CoCensys Presents Phase I Clinical Trial Results for Novel Anti-Convulsant Drug, CCD 1042.IRVINE, Calif.--(HealthWire)--December 4, 1995--CoCensys (Nasdaq: COCN) today announced that results from Phase I clinical trials in 97 healthy adult volunteers for CCD CCD in full charge-coupled device Semiconductor device in which the individual semiconductor components are connected so that the electrical charge at the output of one device provides the input to the next device. 1042, the Company's novel anti-convulsant agent for the treatment of epilepsy, showed that in these trials the drug was well-tolerated after single and multiple dosing. The data were presented today at the 49th Annual Conference of the American Epilepsy Society in Baltimore. CCD 1042 is currently in Phase II clinical trials in pediatric patients with various forms of epilepsy refractory to conventional therapies. In addition, preclinical research conducted at the National Institutes of Health and at CoCensys, and reported at the recent annual meeting of the Society for Neuroscience For other uses, see SFN (disambiguation). The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. , demonstrates that CCD 1042 is active in a broad spectrum of animal models of epilepsy. "In addition to the Phase I safety data which demonstrates CCD 1042 is well tolerated, the initial clinical experience with the compound in ongoing Phase II studies in a small number of pediatric patients with seizures refractory to conventional anticonvulsants Anticonvulsants Drugs used to control seizures, such as in epilepsy. Mentioned in: Antipsychotic Drugs, Osteoporosis has been encouraging," said David A.H. Lee, M.D., Ph.D., Executive Vice President of Research and Development at CoCensys. "The animal data from the NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. study and our own internal research also provides a rationale for extension of the clinical testing of CCD 1042 to include different forms of adult epileptic disorders." CCD 1042 belongs to a class of neurosteroids, known as Epalons, developed by CoCensys. CCD 1042 selectively modulates the Cl- channel of the gamma aminobutyric acid Noun 1. gamma aminobutyric acid - an amino acid that is found in the central nervous system; acts as an inhibitory neurotransmitter GABA amino acid, aminoalkanoic acid - organic compounds containing an amino group and a carboxylic acid group; "proteins are (A) (GABA GABA ?. GABA abbr. gamma-aminobutyric acid GABA (gamma-aminobutyric acid) A neurotransmitter that slows down the activity of nerve cells in the brain. (A)) receptor complex on neurons and can potentiate po·ten·ti·ate v. 1. To make potent or powerful. 2. To enhance or increase the effect of a drug. 3. To promote or strengthen a biochemical or physiological action or effect. GABA-mediated inhibitory responses to produce a calming effect on the central nervous system. In 1994, the U.S. Food & Drug Administration granted CCD 1042 orphan drug designation for West Syndrome, a rare form of epilepsy occurring in infants. CoCensys, Inc. is a biopharmaceutical company that discovers, develops and markets products to treat neurological and psychiatric disorders. The Company's product development programs focus on two novel proprietary classes of compounds: Epalons, to treat epilepsy, anxiety and sleep disorders; and drugs targeting novel receptors associated with NMDA-Ca++ channels, to treat stroke and head trauma, chronic pain and epilepsy. CONTACT: Daniel L. Korpolinski Karen L. Bergman (Media) President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Lilian S. Stern (Investors) CoCensys, Inc. Burns McClellan, Inc. 714/753-6100 212/505-1919 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion